CIC
VTYX

Carnegie Investment Counsel’s Ventyx Biosciences VTYX Stock Holding History

Carnegie Investment Counsel’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,000
Closed -$34.6K – 489
2024
Q2 		$34.6K Hold
15,000
– – ﹤0.01% 465
2024
Q1 		$82.5K Hold
15,000
– – ﹤0.01% 492
2023
Q4 		$37K Hold
15,000
– – ﹤0.01% 481
2023
Q3 		$521K Hold
15,000
– – 0.02% 339
2023
Q2 		$492K Buy
15,000
+5,000
+50% +$172K 0.02% 358
2023
Q1 		$335K Sell
10,000
-5,708
-36% -$222K 0.01% 414
2022
Q4 		$515K Buy
+15,708
New +$465K 0.02% 347

Other funds holding VTYX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Carnegie Investment Counsel's VTYX Position: Q3 2024 in Review

Carnegie Investment Counsel sold out of Ventyx Biosciences (VTYX) in Q3 2024, closing a stake of 15,000 shares — an estimated $34.6K sold.

Carnegie Investment Counsel first reported a position in VTYX in Q4 2022 and held it in 7 quarters. The position peaked at $521K in Q3 2023. 118 funds tracked by Wall St. Rank hold VTYX as of Q3 2024.

  • Carnegie Investment Counsel reported no remaining Ventyx Biosciences position as of Q3 2024 after selling out during the quarter.
  • Carnegie Investment Counsel sold 15,000 Ventyx Biosciences shares in Q3 2024, an estimated $34.6K.
  • Carnegie Investment Counsel first reported a position in Ventyx Biosciences in Q4 2022 and held it in 7 quarters.
  • Carnegie Investment Counsel's Ventyx Biosciences position peaked at $521K in Q3 2023.
  • 118 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2024.

Based on Carnegie Investment Counsel's 13F filing for Q3 2024, filed 10 Oct 2024.